First-Line As-Needed Agents for Anxiety Without Libido Effects
For as-needed (PRN) anxiety management without decreased libido, there are unfortunately no evidence-based first-line pharmacological agents recommended, and you should instead prioritize cognitive behavioral therapy or consider non-PRN daily medications that spare sexual function.
The Core Problem
The available guidelines 1 specifically recommend SSRIs and SNRIs (venlafaxine) as first-line pharmacotherapy for anxiety disorders, but these are daily maintenance medications, not PRN agents. More critically, SSRIs and SNRIs are well-documented to cause sexual dysfunction including decreased libido 2.
Why Benzodiazepines Are Not the Answer
While benzodiazepines are the traditional PRN agents for anxiety, they are explicitly not recommended due to significant risks 3:
- Risk of dependence and adverse effects, especially with long-term use
- Cognitive impairment
- Paradoxically, PRN benzodiazepine use may be associated with reduced anxiolytic efficacy over time and increased patient preference for continued use 4
- The evidence does not support the theoretical advantages of PRN benzodiazepine administration 4
Evidence-Based Alternatives
Behavioral Interventions (Strongest Recommendation)
Cognitive behavioral therapy (CBT) is the first-line behavioral treatment and should be attempted before or alongside any pharmacotherapy 3. The 2023 Japanese guidelines 1 specifically recommend CBT based on the Clark and Wells or Heimberg models delivered by skilled therapists.
- Brief CBT delivered in primary care by embedded behavioral health clinicians is effective 3
- For patients who decline face-to-face CBT, self-help with support based on CBT is suggested 1
Daily Medications That Spare Libido
If pharmacotherapy is needed, consider switching to or starting with agents that have more favorable sexual side effect profiles 2:
- Bupropion (also used as adjunctive treatment for SSRI-induced sexual dysfunction)
- Mirtazapine
- Nefazodone
- Vortioxetine
These are daily medications, not PRN agents, but they address both anxiety and the libido concern.
The PRN Medication Gap
There is a critical gap in the evidence base: Research into as-needed and intermittent benzodiazepine prescription for anxiety is severely lacking 5, despite this being likely the most common administration pattern in clinical practice. The current "anti-benzo" sentiment may be causing problematic underprescription when superior alternatives like CBT are not widely available 5.
Clinical Algorithm
- First: Attempt CBT or brief behavioral interventions 3
- If pharmacotherapy needed: Use daily medications with favorable sexual side effect profiles (bupropion, mirtazapine, nefazodone, or vortioxetine) 2
- Avoid: PRN benzodiazepines due to risks and lack of evidence supporting efficacy 3, 4
- Consider: Collaborative Care Management model involving primary care clinicians, consulting psychiatrists, and care managers 3
Critical Caveat
The main decision in anxiety pharmacotherapy is between daily medication and short-acting PRN medication 3, but the evidence strongly favors daily medications when pharmacotherapy is chosen. For truly intermittent, situational anxiety without meeting full diagnostic criteria for an anxiety disorder, start with self-help and behavioral treatment rather than medication 3.